| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $148,982,284 ) (Continued on the next page) |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | P30CA015704 | Implementing sexual orientation and gender identity data collection in the electronic medical record within diverse cancer care settings | 000 | 48 | NIH | 12/21/2022 | $10,090,142 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | F31CA260920 | Elucidating the role of somatic 3?UTR mutations in prostate cancer pathogenesis | 000 | 4 | NIH | 2/28/2023 | $22,963 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | F31NS118844 | Molecular mechanisms underlying neuronal integrity | 000 | 4 | NIH | 12/12/2022 | $41,188 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01HL147324 | Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemia | 000 | 5 | NIH | 12/8/2022 | $730,616 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01HL147324 | Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemia | 001 | 5 | NIH | 3/4/2023 | $81,178 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R37CA230617 | Hormone signaling and translation control in advanced prostate cancer | 000 | 6 | NIH | 11/30/2022 | $390,546 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | U01CA235625 | Employing CRISPR inactivation screening and in vivo models towards improving treatments for SCLC | 000 | 5 | NIH | 2/28/2023 | $506,274 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UM1AI068618 | CoVPN 3002 A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222 for the Prevention of COVID-19 LC2 | 000 | 18 | NIH | 11/21/2022 | $400,000 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | P30CA015704 | Implementing sexual orientation and gender identity data collection in the electronic medical record within diverse cancer care settings | 001 | 48 | NIH | 12/29/2022 | $194,375 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01CA276308 | Transcriptional-translational conflict in bladder epithelial homeostasis and cancer | 000 | 1 | NIH | 11/28/2022 | $588,061 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01NS119650 | Defining cellular states of quiescence in human brain tumors | 003 | 4 | NIH | 1/31/2023 | $51,544 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01CA234720 | Targeting macrophages in metastatic cancer | 001 | 6 | NIH | 3/15/2023 | $33,933 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01CA234720 | Targeting macrophages in metastatic cancer | 000 | 6 | NIH | 1/24/2023 | $381,746 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01AI175535 | Defining Protective CMV Immunity after Transplantation | 000 | 1 | NIH | 2/6/2023 | $757,310 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01AI170214 | Developing Durable, Env-Boosted CAR T Cells for HIV Cure | 001 | 1 | NIH | 12/8/2022 | $0 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | K23AI163343 | Cytomegalovirus-specific Immune Reconstitution after Hematopoietic Cell Transplantation in the Era of Modern Antiviral Prophylaxis | 000 | 3 | NIH | 1/25/2023 | $189,432 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01NS119650 | Defining cellular states of quiescence in human brain tumors | 002 | 4 | NIH | 1/6/2023 | $463,899 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01CA249528 | Chemotherapy-driven evolution of the vascular secretome and its role in therapeutic resistance | 000 | 4 | NIH | 2/9/2023 | $394,548 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01CA243328 | Tumor-specific autoantibodies for SCLC early detection | 001 | 5 | NIH | 3/14/2023 | $35,251 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01CA243328 | Tumor-specific autoantibodies for SCLC early detection | 000 | 5 | NIH | 11/1/2022 | $396,575 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01NR017951 | An AHEI Dietary Intervention to Reduce Pain in Women with Endometriosis | 001 | 5 | NIH | 2/7/2023 | $50,432 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01NR017951 | An AHEI Dietary Intervention to Reduce Pain in Women with Endometriosis | 000 | 5 | NIH | 12/30/2022 | $453,875 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UM1AI068614 | LOC: HIV Vaccine Trials Network | 006 | 18 | NIH | 1/4/2023 | $14,838,352 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UM1AI068614 | LOC: HIV Vaccine Trials Network | 006 | 18 | NIH | 1/4/2023 | $7,634,355 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01AI170214 | Developing Durable, Env-Boosted CAR T Cells for HIV Cure | 000 | 1 | NIH | 11/2/2022 | $893,464 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01AI167004 | In Vivo Gene Editing of B cells with NICE-AAV Vectors | 000 | 3 | NIH | 11/25/2022 | $125,000 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01HL148189 | Extrinsic regulation of primitive, myeloid-biased hematopoietic stem cells by Semaphorin 4a | 002 | 4 | NIH | 1/31/2023 | $38,983 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | F32CA254805 | Reactivation of an early embryonic program in FSHD and cancer | 000 | 4 | NIH | 11/3/2022 | $69,802 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R37CA240832 | Novel Approaches to CD33-Directed Radioimmunotherapy | 000 | 5 | NIH | 1/30/2023 | $623,487 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01AI150500 | Mathematical modeling of optimal therapeutic combinations for HIV cure | 000 | 5 | NIH | 11/21/2022 | $465,886 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01CA230520 | Mechanisms of treatment failure in chimeric antigen receptor T cell therapy | 000 | 5 | NIH | 2/3/2023 | $489,533 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UM1AI068614 | LOC: HIV Vaccine Trials Network | 006 | 18 | NIH | 1/4/2023 | $250,000 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UM1AI068614 | LOC: HIV Vaccine Trials Network | 006 | 18 | NIH | 1/4/2023 | $500,000 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R21AI173825 | Ontogeny and Function of Early-Life Pulmonary Dendritic Cells | 000 | 1 | NIH | 2/10/2023 | $248,993 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | K99GM149928 | Functional consequences of evolutionary innovation in histone repertoires | 000 | 1 | NIH | 3/6/2023 | $125,000 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01AI171186 | Molecular basis and protective efficacy of cross-neutralizing antibodies against four major respiratory viruses | 000 | 1 | NIH | 3/15/2023 | $814,880 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01AI167004 | In Vivo Gene Editing of B cells with NICE-AAV Vectors | 000 | 3 | NIH | 11/25/2022 | $646,804 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | F31CA260932 | Necrosis-mediated circulating tumor cell dissemination | 000 | 3 | NIH | 2/28/2023 | $42,878 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01HL148189 | Extrinsic regulation of primitive, myeloid-biased hematopoietic stem cells by Semaphorin 4a | 003 | 4 | NIH | 3/3/2023 | $10,798 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R37CA234488 | Role of tumor cell cluster-induced signaling in breast cancer metastasis | 002 | 5 | NIH | 3/14/2023 | $32,208 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01AI140891 | Complete mapping of immune selection from antibodies to HIV | 000 | 6 | NIH | 12/23/2022 | $86,051 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | P01AI138212 | Expansion and targeted maturation of germline HIV-1 bNAb-associated BCRs | 000 | 6 | NIH | 11/17/2022 | $1,900,554 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01CA277133 | Accelerating biomarker development through novel statistical methods for analyzing phase III/IV studies | 000 | 1 | NIH | 11/15/2022 | $413,415 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01HL148189 | Extrinsic regulation of primitive, myeloid-biased hematopoietic stem cells by Semaphorin 4a | 004 | 4 | NIH | 3/15/2023 | -$10,798 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01HL145276 | Harnessing endogenous mechanisms of thymic regeneration toboost immune function in recipients of hematopoietic cell transplant | 001 | 6 | NIH | 3/3/2023 | $57,050 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01HL148189 | Extrinsic regulation of primitive, myeloid-biased hematopoietic stem cells by Semaphorin 4a | 001 | 4 | NIH | 12/28/2022 | $448,040 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01HD103571 | Early and Reinfection in High Risk Women | 000 | 29 | NIH | 2/16/2023 | $916,759 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R37CA234488 | Role of tumor cell cluster-induced signaling in breast cancer metastasis | 001 | 5 | NIH | 11/30/2022 | $362,340 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01HL145276 | Harnessing endogenous mechanisms of thymic regeneration toboost immune function in recipients of hematopoietic cell transplant | 000 | 6 | NIH | 12/31/2022 | $513,455 |
|
